Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 61442-192

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 61442-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carlsbad Technology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

312f5212 E11a 89b4 E063 6394a90ab185

312f5212 E11a 89b4 E063 6394a90ab185
Memantine Hydrochloride Tablets USP are a medication available in 5 mg strength. It is commonly used to treat certain cognitive symptoms related to Alzheimer's disease.*
FDA Label Image

312f529a Ed06 67b8 E063 6294a90a1766

312f529a Ed06 67b8 E063 6294a90a1766
FDA Label Image

Memantine HCl Bl 10mg 500count (Memantine Bl 10mg 500count)

Memantine HCl Bl 10mg 500count (Memantine Bl 10mg 500count)
Each tablet contains 10mg of memantine hydrochloride USP. Keep this and all drugs out of the reach of children. Memantine Hydrochloride is to be dispensed in a tightly closed container as tablets described in the USP. Store at 25°C (77°F) excursions permitted to 15-30°C (59-86°F). Refer to the package insert for dosing and full prescribing information. The provided address is No.36 Zhujiang Road, Shijiazhuang, Hebei, 050035. The relevant NDC for this product is 61442-193-05.*
FDA Label Image

Memantine HCl Bl 5mg 500count (Memantine Bl 5mg 500count)

Memantine HCl Bl 5mg 500count (Memantine Bl 5mg 500count)
Each tablet contains 5mg of memantine hydrochloride, with the NDC code 61442-192-05. It is essential to keep this medication out of the reach of children and to dispense it in a tightly closed container. The tablets should be stored at 25°C (77°F) but can tolerate temperatures between 15-30°C (59-86°F). For dosing instructions and complete prescribing details, refer to the package insert.*
FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 1)

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 1)
This text provides information about the mean change from baseline in ADCS-ADL scores for a placebo group and a group receiving a medication or treatment (possibly HCI). It also mentions categories such as clinical improvement and clinical decline over weeks of treatment.*
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 2)

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 2)
FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 3)

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 3)
FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 4)

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 4)
FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 5)

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 5)
This text appears to describe a graph or table showing changes in ADCS-ADL scores over time for different treatment groups, including placebo, donepezil, and memantine HCl and donepezil together. The data seems to be measured in weeks of treatment.*
FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 6)

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 6)
This text provides information about the Cumulative Percentage of Patients for two different treatments, Picebollonepezil and Nernarfine HliDonepezil, across different levels of ADCS-ADL change from Baseline. It displays a graph showing the distribution of patients in each treatment group based on their observed changes in ADCS-ADL scores.*
FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 7)

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 7)
FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 8)

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 8)
FDA Label Image

Memantine Structure (Memantine Structure)

Memantine Structure (Memantine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.